Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 1.00 |
| ▸ | TK2 | O00142 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982019 | 1.00 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL5982016 | 1.00 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL2396529 | 1.00 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273340 | 1.00 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Phosphoric Acid SCHEMBL3241651 | 0.96 | TK1 (0.92) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1532525 | 0.93 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13252712 | 0.93 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1532524 | 0.93 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273573 | 0.93 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273343 | 0.93 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2019-05-16 | — | — | US | claimed |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2017-02-09 | — | — | US | claimed |
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2015-01-08 | — | — | US | claimed |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2011-09-08 | — | — | US | claimed |
| US-8513205-B2 | Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase | YALE UNIVERSITY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110312880-A1 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | ANDERSON KAREN S (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2009126293-A2 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | YALE UNIVERSITY (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20060142311-A1 | Prodan-containing nucleotide and use thereof | KYOTO UNIVERSITY | 2006-06-29 | — | — | US | disclosed |
| WO-2004053153-A1 | A REAGENT AND METHOD FOR DETERMINING THE SIZE OF POLYNUCLEOTIDES | NUCLEICS PTY LTD (AU) | 2004-06-24 | — | — | WO | disclosed |
| EP-0272446-B1 | NOVEL ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0257378-B1 | PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1991-07-03 | — | — | EP | disclosed |
| US-5010060-A | Method of treating herpes simplex viral infection employing pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1991-04-23 | — | — | US | disclosed |
| US-4841039-A | 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents | EMORY UNIVERSITY (US) | 1989-06-20 | — | — | US | disclosed |
| EP-0274025-A2 | Novel antiviral agents | SRI INTERNATIONAL (US) | 1988-07-13 | — | — | EP | disclosed |
| EP-0273169-A2 | Novel antiviral agents | SRI INTERNATIONAL (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0258412-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER, Sheldon B. (US) | 1988-03-09 | — | — | EP | disclosed |
| WO-1987004929-A1 | COMPOSITION FOR AND METHOD OF TREATING AIDS AND CERTAIN RELATED DISEASES | GREER SHELDON B | 1987-08-27 | — | — | WO | disclosed |
| US-4681933-A | 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1987-07-21 | — | — | US | disclosed |
| WO-1984004748-A2 | NOVEL ANTIVIRAL AGENTS | — | 1984-12-06 | — | — | WO | disclosed |
| US-4210638-A | 5-TRIFLUOROMETHYL-2'-DEOXYCYCTIDINE AND TETRAHYDROURIDINE OR 2'-DEOXYTETRAHYDROURIDINE | PCR, INC. (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | TK1 78/4885TK2 1838/4885LMNA 1691/4885 |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | TK1 78/4885TK2 1838/4885LMNA 1691/4885 |
| US-20110312880-A1 | POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | NAMPT, NAPRT, DNTT | TK1 61/4885TK2 274/4885LMNA 4587/4885 |
| US-20060142311-A1 | Prodan-containing nucleotide and use thereof | PNP, NUDT1, NT5C2 | TK1 201/4885TK2 346/4885LMNA 152/4885 |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, MGMT | TK1 78/4885TK2 1652/4885LMNA 1543/4885 |
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | TK1 78/4885TK2 1838/4885LMNA 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.